BBHC
BCRX icon

Brown Brothers Harriman & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19K Hold
219
– – ﹤0.01% 1715
2026
Q1 		$2.08K Hold
219
– – ﹤0.01% 1682
2025
Q4 		$1.71K Hold
219
– – ﹤0.01% 1743
2025
Q3 		$1.66K Hold
219
– – ﹤0.01% 1595
2025
Q2 		$1.96K Buy
+219
New +$2.04K ﹤0.01% 1415
2023
Q2 		– Sell
-13,000
Closed -$108K – 1227
2023
Q1 		$108K Buy
+13,000
New +$125K ﹤0.01% 592

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Brown Brothers Harriman & Co's BCRX Position: Q2 2026 in Review

Brown Brothers Harriman & Co held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 219 shares worth $2.19K. The position accounts for ﹤0.01% of the portfolio, ranked #1715.

Brown Brothers Harriman & Co first reported a position in BCRX in Q1 2023 and has held it in 6 quarters since. The position peaked at $108K in Q1 2023. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Brown Brothers Harriman & Co held 219 shares of BioCryst Pharmaceuticals worth $2.19K as of Q2 2026.
  • Brown Brothers Harriman & Co left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Brown Brothers Harriman & Co's portfolio in Q2 2026, its #1715 holding.
  • Brown Brothers Harriman & Co first reported a position in BioCryst Pharmaceuticals in Q1 2023 and has held it in 6 quarters since.
  • Brown Brothers Harriman & Co's BioCryst Pharmaceuticals position peaked at $108K in Q1 2023.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2026, filed 12 Aug 2026.